Go Deep
Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,236 | -2.3 | 1.97 | 0.06 | 1,641.83 |
| Oct 2026 | 20,382 | -2.2 | 1.89 | 0.06 | 1,576.13 |
| Oct 2026 | 20,160 | -2.4 | 2.00 | 0.06 | 1,668.47 |
| Oct 2026 | 20,252 | -2.3 | 1.96 | 0.06 | 1,626.26 |
| Oct 2026 | 19,994 | -2.4 | 2.06 | 0.06 | 1,716.18 |
| Oct 2026 | 19,789 | -2.5 | 2.17 | 0.06 | 1,800.56 |
| Oct 2026 | 19,787 | -2.5 | 2.17 | 0.06 | 1,797.06 |
| Oct 2026 | 19,814 | -2.5 | 2.18 | 0.06 | 1,800.98 |
Odyssey Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 959,000.0 | 1,918,000.0 |
| Net Profit | -52,788,000.0 | -38,262,000.0 | -41,235,000.0 | -38,435,000.0 |
| EPS | -1.7 | -0.8 | -1.5 | -1.4 |
Odyssey Therapeutics, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 2,976,000.0 | 4,472,000.0 | 1,037,000.0 | 0.0 |
| Net Profit | -148,647,000.0 | -129,321,000.0 | -125,938,000.0 | -124,665,000.0 |
| EPS | -5.4 | -4.7 | -1.3 | -4.5 |
Odyssey Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total Assets | 269,788,000.0 | 197,435,000.0 | 286,521,000.0 | 317,150,000.0 |
| Total Liabilities | 758,066,000.0 | 579,962,000.0 | 549,229,000.0 | 461,770,000.0 |
| Total Equity | -488,278,000.0 | -382,527,000.0 | -262,708,000.0 | -144,620,000.0 |
Owes vs Owns
Odyssey Therapeutics, Inc. owed $0.13 for every $1 it owned in Jun 2026, down from $1.46 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.13× | 2.81× | 2.94× | 1.92× | 1.46× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Odyssey Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 67.2%Fixed assets (tangible) 9.6%Intangible assets 5.4%Long-term investments 13.0%Other assets 4.7%
How it's funded — Dec 2025
Short-term debt 0.7%Long-term debt 2.9%Payables 1.0%Other liabilities 95.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 181.4 | 129.4 | 187.0 | 241.0 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 26.0 | 39.5 | 46.7 | 52.8 |
| Intangible assets | 14.6 | 13.9 | 14.5 | 14.1 |
| Long-term investments | 35.2 | 0.0 | 29.1 | 0.0 |
| Other assets | 12.6 | 14.7 | 9.2 | 9.3 |
| Liabilities & equity | ||||
| Short-term debt | 5.2 | 4.6 | 3.9 | 3.4 |
| Long-term debt | 21.9 | 26.4 | 30.5 | 4.8 |
| Payables | 7.9 | 6.3 | 7.7 | 8.1 |
| Other liabilities | 723.1 | 542.6 | 507.1 | 445.6 |
| Shareholders' equity | -488.3 | -382.5 | -262.7 | -144.6 |
| Net tangible assets | -502.9 | -396.4 | -277.2 | -158.7 |
Odyssey Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | -129,468,000.0 | -117,471,000.0 | -112,728,000.0 | -99,842,000.0 |
| Investing Activities | -103,943,000.0 | 96,784,000.0 | -165,020,000.0 | -13,027,000.0 |
| Financing Activities | 215,646,000.0 | 26,979,000.0 | 92,076,000.0 | 182,717,000.0 |